tiprankstipranks
Bluebird Bio reports Q3 EPS (31c), consensus (35c)
The Fly

Bluebird Bio reports Q3 EPS (31c), consensus (35c)

Reports Q3 revenue $10.60M , consensus $18.68M.”Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial launches continued to accelerate,” said Andrew Obenshain, chief executive officer. “This momentum, coupled with steps we took in the third quarter to increase manufacturing capacity for ZYNTEGLO and optimize our cost structure, is propelling bluebird forward on our path to becoming a sustainable commercial gene therapy company. We remain focused on securing additional cash resources to extend our runway, which we believe would enable us to achieve this vision and reach cash flow break-even in the second half of 2025.”

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App